Jan 28 (Reuters) - BIOAGE Labs Inc BIOA.O:
BIOAGE LABS ANNOUNCES COMPANY UPDATES ON APJ, NLRP3, AND PLATFORM PROGRAMS
BIOAGE LABS: NOMINATION OF NLRP3 INHIBITOR BGE-102 AS A DEVELOPMENT CANDIDATE, WITH INITIAL PH1 CLINICAL DATA ANTICIPATED BY END OF 2025
Source text: ID:nGNX4tHV5V
Further company coverage: BIOA.O